Johannes Zanzinger

Johannes Zanzinger has made 39 investments in companies such as: Aignostics, T3 Pharmaceuticals, Dopavision, Topas Therapeutics, Actym, eTheRNA immunotherapies, STAT-Dx, Rinri Therapeutics, Rigontec, Hookipa Pharma, Tacalyx, NBE-Therapeutics, Aelin Therapeutics, Okairos, ImCheck Therapeutics, Wellth, T-knife, Brainomix, Acousia Therapeutics, Rgenta Therapeutics, DiogenX, Cardior Pharmaceuticals, Delonix Bioworks, Bodyport, Ruipeng Pet Healthcare, Metabomed, ArmaGen Technologies, Rewind Therapeutics, HepaRegeniX, Perfood, Eyevensys, Promethera Biosciences, Sentien Biotechnologies, Amal Therapeutics, Vira Therapeutics, OncoMyx Therapeutics, Libra Therapeutics, Abalos Therapeutics, AgomAb Therapeutics.

Location of Johannes Zanzinger is Ingelheim am Rhein, Germany.

The free version of Angel Match provides limited data for Johannes Zanzinger. Advanced features and premium data such as emails, phone numbers and social media profiles are available only on paid subscription plans.

Johannes Zanzinger is a Investment Manager and he his investment types are: Corporate Venture Capital.
Johannes Zanzinger focuses investing in industries such as: Biotechnology, Medical, Health Care, Therapeutics, Personal Health, Wellness, Advanced Materials, Chemical, Chemical Engineering, Beauty, Hospital, Artificial Intelligence, Health Diagnostics, Machine Learning, Software, Women Founded.

A short brief about investor:


Past investments

  • Aignostics
  • T3 Pharmaceuticals
  • Dopavision
  • Topas Therapeutics
  • Actym
  • eTheRNA immunotherapies
  • STAT-Dx
  • Rinri Therapeutics
  • Rigontec
  • Hookipa Pharma
  • Tacalyx
  • NBE-Therapeutics
  • Aelin Therapeutics
  • Okairos
  • ImCheck Therapeutics
  • Wellth
  • T-knife
  • Brainomix
  • Acousia Therapeutics
  • Rgenta Therapeutics
  • DiogenX
  • Cardior Pharmaceuticals
  • Delonix Bioworks
  • Bodyport
  • Ruipeng Pet Healthcare
  • Metabomed
  • ArmaGen Technologies
  • Rewind Therapeutics
  • HepaRegeniX
  • Perfood
  • Eyevensys
  • Promethera Biosciences
  • Sentien Biotechnologies
  • Amal Therapeutics
  • Vira Therapeutics
  • OncoMyx Therapeutics
  • Libra Therapeutics
  • Abalos Therapeutics
  • AgomAb Therapeutics

Social media:

Available after registration.